Last update 11 Jul 2024

Cetrelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Cetrelimab (USAN/INN)
+ [1]
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

External Link

KEGGWikiATCDrug Bank
D11488--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Muscle Invasive Bladder Urothelial CarcinomaPhase 3
UA
07 Dec 2020
Muscle Invasive Bladder Urothelial CarcinomaPhase 3
DE
07 Dec 2020
Muscle Invasive Bladder Urothelial CarcinomaPhase 3
ES
07 Dec 2020
Muscle Invasive Bladder Urothelial CarcinomaPhase 3
GR
07 Dec 2020
Plasma cell myeloma refractoryPhase 2
BE
16 Nov 2017
Plasma cell myeloma refractoryPhase 2
ES
16 Nov 2017
Plasma cell myeloma refractoryPhase 2
IL
16 Nov 2017
Relapse multiple myelomaPhase 2
IL
16 Nov 2017
Relapse multiple myelomaPhase 2
ES
16 Nov 2017
Relapse multiple myelomaPhase 2
BE
16 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
26
(gzvuohjgcb) = ointwuayfu kstrykqxqz (znvbjsdjvr )
Positive
30 Apr 2023
(gzvuohjgcb) = lwogbzwbqg kstrykqxqz (znvbjsdjvr )
Phase 1/2
413
xjynxlwttk(bhftxoxjut) = Grade ≥ 3 adverse events (AEs) occurred in 53.9% of patients jniksacpfd (uzukaqzghz )
Positive
17 Mar 2022
Phase 2
Transitional Cell Carcinoma
First line
FGFR Mutation
53
(ojhnhsewkm) = Hyperphosphatemia (ERDA vs ERDA + CET, 58% vs 58%), stomatitis (63% vs 54%), and diarrhea (50% vs 42%). phvzmjszta (kjugkdtymh )
Positive
17 Sep 2021
Phase 2/3
10
Daratumumab+Cetrelimab
(safety run-in phase)
(pzgyagxewv) = In the safety run-in, 7 (77.7%) patients had ≥ 1 infusion-related reaction (most grade 1-2), and 1 had a grade 2 immune-mediated reaction edoclgvcex (ypksiwrujb )
Negative
01 Jan 2021
Daratumumab+Cetrelimab
Phase 1/2
22
(rjtweexyca) = budojdkqvb qrtfshmwbx (zlvrsxswar )
Positive
17 Sep 2020
(rjtweexyca) = secnyzsgbn qrtfshmwbx (zlvrsxswar )
Phase 1/2
162
(xhsdpuahhu) = Duration of treatment was 8.1 mos (range, 0.0-24.7) for NSCLC; 5.5 mos (range, 0.0-25.0) for MEL; and for 3.0 mos (0.0-16.1) for CRC. emeakypeqr (wbhzoygawu )
-
25 May 2020
Phase 2
15
glmfvqxvcb(kxuolgduzy) = serious unrelated AE wokecyaalh (tlxffckbzc )
-
19 Feb 2020
Phase 2/3
10
(Part 1: Daratumumab + JNJ-63723283)
rnweighmsg(lrkdrqyzvq) = nqomtwuajw kanvuscsne (jgotbdnjxu, pktvxwaqng - xqzcvktjrj)
-
12 Nov 2019
(Part 2: Daratumumab (Arm A))
dvomjimdrn(rzkwsyvkfi) = vkmukcywfi xtqgknwyix (dfflwgnuem, skpoffqxma - xavsyhkrof)
Phase 2
136
(byzwumcpxk) = bgawkhfwbu cvojunyemo (tranjycimv )
-
26 May 2019
(byzwumcpxk) = bptdqkdycw cvojunyemo (tranjycimv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free